Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | F7 | P08709 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | F3 | P13726 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713806 | 1.00 | ALDH1A1 (0.30) | ALDH1A1F7ADORA3CYP19A1F3 | |
| SCHEMBL725620 | 0.83 | TSHR (0.38) | ALDH1A1LMNATSHR | |
| SCHEMBL340710 | 0.83 | TSHR (0.38) | ALDH1A1LMNATSHR | |
| SCHEMBL1819117 | 0.82 | F7 (0.39) | ALDH1A1F7CYP19A1F3PTGS1 | |
| SCHEMBL1819114 | 0.82 | F7 (0.39) | ALDH1A1F7CYP19A1F3PTGS1 | |
| SCHEMBL8710141 | 0.82 | ALDH1A1 (0.32) | ALDH1A1F7CYP19A1F3PTGS1 | |
| SCHEMBL8710139 | 0.82 | ALDH1A1 (0.32) | ALDH1A1F7CYP19A1F3PTGS1 | |
| SCHEMBL317103 | 0.80 | ALDH1A1 (0.33) | ALDH1A1F7CYP19A1F3PTGS1 | |
| SCHEMBL14937122 | 0.80 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL317104 | 0.80 | ALDH1A1 (0.33) | ALDH1A1F7CYP19A1F3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592698-B1 | PHOSPHINE COMPOUND, INTERMEDIATE, PALLADIUM-COMPLEX, AND USE THEREOF | TAKASAGO PERFUMERY CO LTD (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-7129367-B2 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-0623622-B1 | PROCESS FOR PRODUCING CEPHEM COMPOUND | OTSUKA KAGAKU KK (JP) | 1999-10-06 | — | — | EP | disclosed |
| US-5656754-A | REACTING AN ALLENYL-B-LACTAM COMPOUND WITH AN ORGANOTIN COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-08-12 | — | — | US | disclosed |
| EP-0623622-A1 | PROCESS FOR PRODUCING CEPHEM COMPOUND | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058542-A1 | Phosphine compound, its intermediate, its complex with palladium and a manufacturing method of unsaturated compounds by using the palladium complex | SQLE, C9, PHOSPHO1 | ALDH1A1 2617/4885F7 143/4885ADORA3 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.